Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.48 |
| ▸ | APLNR | P35414 | 2/20 | 0.48 |
| ▸ | CCR6 | P51684 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488114 | 0.88 | RAB9A (0.46) | RAB9AHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL4493011 | 0.83 | AGTR1 (0.51) | RAB9AHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL4502305 | 0.81 | PKM (0.47) | RAB9AHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL4502723 | 0.81 | PKM (0.47) | RAB9AHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL14816982 | 0.81 | PKM (0.49) | HSP90AA1KMT2ACYP1A2CYP2C19CA2 | |
| SCHEMBL13713053 | 0.80 | KMT2A (0.46) | RAB9AHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL4494656 | 0.80 | CYP1A2 (0.50) | RAB9AHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL4503359 | 0.79 | AGTR1 (0.44) | RAB9AHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL4489584 | 0.79 | AGTR1 (0.44) | RAB9AHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL13713054 | 0.79 | AGTR1 (0.54) | RAB9AHSP90AA1CXCR5APLNRCCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585883-B2 | Substituted pyridines and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585883-B2 | Substituted pyridines and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585883-B2 | Substituted pyridines and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1817303-A2 | SUBSTITUTED PYRIDINES WITH ACTIVITY ON SYK KINASE | Rigel Pharmaceuticals, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060178407-A1 | Substituted pyridines and their uses | RIGEL PHARMACEUTICAL, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006050480-A2 | SUBSTITUTED PYRIDINES WITH ACTIVITY ON SYK KINASE | RIGEL PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178407-A1 | Substituted pyridines and their uses | KIT, CPA3, CMA1 | RAB9A 2557/4885HSP90AA1 3864/4885CXCR5 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.